Jay Cui

Jay joined Abingworth’s Menlo Park office in August 2021, bringing more than 15 years of experience in investment, consulting, and academic research in the life sciences industry.

Previously, Jay was a Director at AbbVie Ventures, the corporate venture capital arm of AbbVie, focusing on early-stage biotech investments. He played an instrumental role in their investments in Accent Therapeutics and Caribou Biosciences (NASDAQ: CRBU) and supported portfolio companies including Disarm Therapeutics (acquired by Lilly) and Jnana Therapeutics. Jay was also responsible for sourcing multiple seed-stage opportunities and formulating theses in key investment areas. Before AbbVie, Jay worked as a management consultant at ZS Associates and as the leader of an NIH-funded drug discovery research lab in Chicago.